A Study of Apabetalone in Subjects With Long -COVID
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2025-04-18
- Lead Sponsor
- Resverlogix Corp
- Target Recruit Count
- 200
- Registration Number
- NCT06590324
- Locations
- 🇯🇴
The Speciality Hospital, Amman, Jordan
🇸🇦MNGHA- King Abdulaziz Hospital, Al Mubarraz, Saudi Arabia
🇦🇪Al Kuwait Hospital, Dubai, United Arab Emirates
An Open-Label Study of Apabetalone in Covid Infection
- First Posted Date
- 2021-05-20
- Last Posted Date
- 2023-11-18
- Lead Sponsor
- Resverlogix Corp
- Target Recruit Count
- 1
- Registration Number
- NCT04894266
- Locations
- 🇨🇦
University of Alberta, Edmonton, Alberta, Canada
Safety and Effect of Oral RVX000222 in Subjects With Fabry Disease
- First Posted Date
- 2017-07-25
- Last Posted Date
- 2023-11-18
- Lead Sponsor
- Resverlogix Corp
- Registration Number
- NCT03228940
- Locations
- 🇨🇦
Queen Elizabeth II Health Sciences Centre, Victoria General Site, Halifax, Nova Scotia, Canada
A Two-Part Phase 2a Study of RVX000222 in Patients With End-Stage Renal Disease Treated With Hemodialysis
Phase 1
Not yet recruiting
- Conditions
- Kidney Failure, Chronic
- Interventions
- Drug: Placebos
- First Posted Date
- 2017-05-19
- Last Posted Date
- 2023-11-15
- Lead Sponsor
- Resverlogix Corp
- Target Recruit Count
- 44
- Registration Number
- NCT03160430
Effect of RVX000222 on Time to Major Adverse Cardiovascular Events in High-Risk T2DM Subjects With CAD
Phase 3
Completed
- Conditions
- Diabetes Mellitus, Type 2Coronary Artery Disease
- Interventions
- First Posted Date
- 2015-10-26
- Last Posted Date
- 2021-08-20
- Lead Sponsor
- Resverlogix Corp
- Target Recruit Count
- 2425
- Registration Number
- NCT02586155
- Locations
- 🇭🇷
Clinical Hospital Sveti duh, Zagreb, Croatia
🇧🇪AZ Turnhout, Turnhout, Belgium
🇮🇱Kaplan Medical Center, Rehovot, Israel
Characterization of Multi-dose RVX000222 in Combination With Statin Treatment in Dyslipidemia
Phase 2
Terminated
- Conditions
- DyslipidemiaCoronary Artery Disease
- Interventions
- First Posted Date
- 2013-05-27
- Last Posted Date
- 2015-05-12
- Lead Sponsor
- Resverlogix Corp
- Target Recruit Count
- 13
- Registration Number
- NCT01863225
- Locations
- 🇦🇺
Royal Adelaide Hospital / CMAX, Adelaide, South Australia, Australia
The Effects of RVX000222 on Glucose Metabolism in Individuals With Pre-diabetes
- First Posted Date
- 2012-11-19
- Last Posted Date
- 2014-04-02
- Lead Sponsor
- Resverlogix Corp
- Target Recruit Count
- 20
- Registration Number
- NCT01728467
- Locations
- 🇦🇺
Baker IDI Heart and Diabetes Institute 75 Commercial Road,, Melbourne, Victoria, Australia
The Study of Quantitative Serial Trends in Lipids With ApolpoproteinA-I Stimulation
Phase 2
Completed
- Conditions
- Coronary Artery DiseaseDyslipidemia
- Interventions
- Drug: Placebo RVX000222
- First Posted Date
- 2011-08-25
- Last Posted Date
- 2012-09-20
- Lead Sponsor
- Resverlogix Corp
- Target Recruit Count
- 176
- Registration Number
- NCT01423188
ApoA-I Synthesis Stimulation and Intravascular Ultrasound for Coronary Atheroma Regression Evaluation
Phase 2
Completed
- Conditions
- Coronary Artery Disease
- Interventions
- Drug: Placebo RVX000222
- First Posted Date
- 2010-02-12
- Last Posted Date
- 2013-06-04
- Lead Sponsor
- Resverlogix Corp
- Target Recruit Count
- 324
- Registration Number
- NCT01067820
Clinical Trial for Dose Finding and Safety of RVX000222 in Subjects With Stable Coronary Artery Disease
Phase 2
Completed
- Conditions
- AtherosclerosisCoronary Artery Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2010-01-28
- Last Posted Date
- 2023-04-03
- Lead Sponsor
- Resverlogix Corp
- Target Recruit Count
- 299
- Registration Number
- NCT01058018
- Locations
- 🇺🇸
Orange County Research Center, Tustin, California, United States
© Copyright 2025. All Rights Reserved by MedPath